{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:05:08Z","timestamp":1789909508888,"version":"4.0.1"},"reference-count":21,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2006]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Genital warts are a common sexually transmitted disease caused by human papillomaviruses. Podophyllotoxin 0.5%, approved for patient self-administration, has been used most extensively in the treatment of genital warts. Imiquimod, a novel immune response modifier capable of inducing interferon-\u03b1 and a variety of cytokines, has been examined as a potential treatment for genital warts. But 0.5% podophyllotoxin and 5% imiquimod have not been compared in any extensive and formal studies, although they are the common topical agents for genital warts. &lt;i&gt;Objective:&lt;\/i&gt; To evaluate the efficacy and safety of topical 5% imiquimod and 0.5% podophyllotoxin in the treatment of genital warts. &lt;i&gt;Methods:&lt;\/i&gt; We searched Medline (1966 to June 2005), Embase (1974 to June 2005) and the Cochrane Controlled Trials Register (issue 3, 2005). Randomized controlled trials of 5% imiquimod or 0.5% podophyllotoxin in the treatment of genital warts were collected. Two reviewers extracted the data and independently assessed the quality of the included medical literature. Then, meta-analysis was conducted. &lt;i&gt;Results:&lt;\/i&gt; Twelve studies including 3 placebo-controlled trials of imiquimod and 9 placebo-controlled trials of podophyllotoxin were included. The clinical cure rates of imiquimod and podophyllotoxin were 50.34 and 56.41%, respectively, without statistically significant differences between the two (p &gt; 0.05). A combined analysis of the 3 studies on imiquimod showed a statistically significant difference to the placebo group [pooled odds ratio (OR) 11.65, 95% confidence interval (CI) 6.05\u201322.44], as did a combined analysis of the 9 studies on podophyllotoxin (pooled OR 16.70, 95% CI 7.06\u201339.48). The most common adverse events of imiquimod were erythema, erosion, excoriation, itching and burning; those of podophyllotoxin were burning, pain, erosion, itching and inflammation. &lt;i&gt;Conclusion:&lt;\/i&gt; Imiquimod and podophyllotoxin possess similar curative effects on condylomata acuminata but podophyllotoxin has more serious adverse effects.<\/jats:p>","DOI":"10.1159\/000095039","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T11:18:07Z","timestamp":1160479087000},"page":"218-223","source":"Crossref","is-referenced-by-count":58,"title":["Meta-Analysis of 5% Imiquimod and 0.5% Podophyllotoxin in the Treatment of Condylomata Acuminata"],"prefix":"10.1159","volume":"213","author":[{"given":"Jun","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2006,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2F0166-3542%2894%2990066-3"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9343%2897%2900177-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS0002-9343%2897%2900181-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM198509263131304"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165%2F00063030-199911050-00004"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2FS0190-9622%2898%2970243-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.134.1.25"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2889%2992282-4"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2890%2990424-C"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097%2F00007435-199205000-00012"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159%2F000246818"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159%2F000246530"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.134.1.33"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2894%2990168-6"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080%2F01443619866606"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097%2F00007435-200302000-00006"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199802123380703"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136%2Fsti.79.4.270"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016%2FS0020-7292%2801%2900573-2"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097%2F00007435-200104000-00007"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1258%2F0956462011916695"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/95039","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/95039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:37:51Z","timestamp":1745447871000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000095039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000095039","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}